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Background
A high prevalence of anal squamous intraepithelial
lesions (ASIL) and HPV infection have been observed in
HIV-infected MSM in the pre-cART era. To date, the
impact of cART on the natural history of HPV infection
and ASIL is poorly documented.
Methods
94 HIV-infected MSM naïve of cART were enrolled in
a longitudinal study before starting a first-line regimen
of cART. Each patient provided anal samples for cytol-
ogy, histology, and HPV DNA testing at baseline,
month 12, and month 24 of cART. HPV DNA was
detected by real-time PCR and Roche Linear Array
assay. Anal cytologic was processed by the Thin Prep™
method (Hologic). CD4+ and CD8+ T cell responses
to HPV-16 E6 and E7 proteins were measured in a
subgroup of individuals exhibiting HPV-16 anal infec-
tion at inclusion.
Results
Prevalence of low-grade SIL, high-grade SIL, and HPV
infection was similar at M12 compared to baseline.
Among patients with normal cytology and/or histology
at baseline, 44% progressed to SIL at M12 whereas 31%
of patients with ASIL at baseline exhibited a regression
at M12. Specific anti-HPV CD4 T cell responses were
mostly undetectable both at baseline and M12. (Table 1
and 2)
At month 12, prevalence of anal HPV DNA detection
was similar than at baseline. High-risk HPV was
detected at month 12 in 92% of the patients with high-
risk HPV infection at baseline. Low-risk HPV was
detected at month 12 in 91% of the patients with low-
risk HPV infection at baseline. HPV-16 and HPV-18
were detected at month 12 in 13% and 3.7% of patients
with no HPV-16 and HPV 18 infection at baseline,
respectively. HPV-16 was detected in 100% and 70% of
high-grade SIL at baseline and month 12, respectively.
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Table 1 The median age of the patients was 39.7 years (33.2-43.5). Baseline and month 12 cytologic and/or histologic
results
CD4/mm
3 median
(Q1-Q3)
Plasma HIV RNA log10
copies/mL
VL
<50
Prior AIDS
event
Visible
lesion
Presence of
condyloma
Anal
SIL
Low-grade SIL; High-
grade SIL
Baseline 299 (242 – 342) 4.8 (4.17 – 5.26) 1% 4 (4%)
40/94
(43%) 23/94 (25%)
51
(54%) 30 (32%); 8 (9%)
M12 500 (411 – 575) 1.6 (1.6 – 1.6) 93%
25/71
(35%) 5/71 (7%)
41
(58%) 24 (34%); 10 (14%)
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Our results demonstrate a high prevalence and inci-
dence of ASIL and anal HPV infection in HIV-infected
MSM despite CD4 recon-stitution under cART. These
data suggest that all HIV-positive MSM, even under
antiretroviral therapy, remain at risk of anal SIL.
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Table 2 Baseline and month 12 virological results
Number of HPV
Number of high-risk and
low-risk type High risk HPV HPV-16 HPV-18 HPV-16 DNAlog10 copies/10
6 cells
Baseline 5 (2 – 7) 3 (2 – 5); 2 (1 – 4) 83 (90%) 49 (53%) 28 (30%) 6.1 (5.3 – 7.1)
M12 5 (2 – 6) 3 (1 – 4); 2 (1 – 4) 59 (87%) 28 (41%) 15 (22%) 6.1 (2.0 – 7.2)
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